Merck & Co. (MRK)
Technical, fundamental, and sentiment analysis with recent related videos.
MRK rates Neutral overall. The fundamental read is neutral: the company passes 4 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 4.45); revenue is growing about 3.1% per year; net income is declining about 45.5% per year. The technical picture is bullish: price is 16.6% above the 200-day moving average; 0.7% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is neutral (composite 60/100), based on 6 news articles and 3 qualified videos from recent coverage.
Revenue 3-year avg +3.1%. Net income 3-year avg -45.5%.
Price vs 20DMA +0.1%. RSI 49.65. Bollinger state: Inside Bands.
Composite score 60/100 from the AI judge, based on 6 news items, 0 television segments, and 3 videos.
Latest Market Read
Merck’s badges split. The Fundamental rating is Neutral because revenue averaged 3.1 percent per year while net income averaged -45.5 percent per year, so profits weaken even as sales tick up. The Technical badge is Bullish: price sits about 0.1 percent above the 20-day moving average (20-day moving average), the Relative Strength Index (RSI), a momentum reading, is 49.6, and the stock trades inside its Bollinger Bands. Sentiment is Neutral at a 60/100 composite; coverage highlights clinical upside but the score keeps the label at Neutral. The three ratings combine to an overall Neutral reading.
Recent news: Coverage from the Global Database of Events, Language, and Tone (GDELT) and Internet Archive TV coverage focused on two clinical stories, Phase 3 INTerpath‑001 showing Intismeran plus Keytruda cut recurrence or death by 42 percent with NEJM acceptance, and competing olomorasib plus Keytruda data, alongside Merck’s modest Q3 revenue beat. Reporters also noted a large Q3 institutional sale and investor selling after a leaked Moderna‑Merck vaccine data set; recent videos tracked the vaccine fallout and CEO comments on faster manufacturing.